132 related articles for article (PubMed ID: 8868205)
1. Hostility in heroin abusers subtypes: fluoxetine and naltrexone treatment.
Gerra G; Fertonani G; Zaimovic A; Rota-Graziosi I; Avanzini P; Caccavari R; Delsignore R; Lucchini A
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Dec; 19(8):1225-37. PubMed ID: 8868205
[TBL] [Abstract][Full Text] [Related]
2. Aggressive responding in abstinent heroin addicts: neuroendocrine and personality correlates.
Gerra G; Zaimovic A; Moi G; Bussandri M; Bubici C; Mossini M; Raggi MA; Brambilla F
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):129-39. PubMed ID: 14687867
[TBL] [Abstract][Full Text] [Related]
3. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
Krupitsky EM; Zvartau EE; Masalov DV; Tsoy MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
J Subst Abuse Treat; 2006 Dec; 31(4):319-28. PubMed ID: 17084785
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone and buprenorphine combination in the treatment of opioid dependence.
Gerra G; Fantoma A; Zaimovic A
J Psychopharmacol; 2006 Nov; 20(6):806-14. PubMed ID: 16401652
[TBL] [Abstract][Full Text] [Related]
5. [Naltrexone and fluoxetine for maintenance of remission in patients with heroin addiction: a double-blind randomized placebo-controlled trial].
Krupitskiĭ EM; Zvartau EE; Tsoĭ-Podosenin MV; Masalov DV; Burakov AM; Egorova VIu; Didenko TIu; Romanova TN; Ivanova EB; Bespalov AIu; Verbitskaia EV; Neznanov NG; Grineneko AIa; O'Brien C; Woody D
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 2):44-54. PubMed ID: 21322147
[TBL] [Abstract][Full Text] [Related]
6. Aggressive responding of male heroin addicts under methadone treatment: psychometric and neuroendocrine correlates.
Gerra G; Zaimovic A; Raggi MA; Giusti F; Delsignore R; Bertacca S; Brambilla F
Drug Alcohol Depend; 2001 Dec; 65(1):85-95. PubMed ID: 11714593
[TBL] [Abstract][Full Text] [Related]
7. Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence.
Lalanne L; Ayranci G; Filliol D; Gavériaux-Ruff C; Befort K; Kieffer BL; Lutz PE
Addict Biol; 2017 Jul; 22(4):1010-1021. PubMed ID: 27001273
[TBL] [Abstract][Full Text] [Related]
8. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
Zaaijer ER; van Dijk L; de Bruin K; Goudriaan AE; Lammers LA; Koeter MW; van den Brink W; Booij J
Psychopharmacology (Berl); 2015 Jul; 232(14):2597-607. PubMed ID: 25757673
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts.
Landabaso MA; Iraurgi I; Jiménez-Lerma JM; Sanz J; Fernádez de Corres B; Araluce K; Calle R; Gutiérrez-Fraile M
Addiction; 1998 May; 93(5):739-44. PubMed ID: 9692272
[TBL] [Abstract][Full Text] [Related]
10. Effects of olanzapine on aggressiveness in heroin dependent patients.
Gerra G; Di Petta G; D'Amore A; Iannotta P; Bardicchia F; Falorni F; Coacci A; Strepparola G; Campione G; Lucchini A; Vedda G; Serio G; Manzato E; Antonioni M; Bertacca S; Moi G; Zaimovic A
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1291-8. PubMed ID: 16766110
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine and behavioural responses to opioid receptor-antagonist during heroin detoxification: relationship with personality traits.
Gerra G; Ceresini S; Esposito A; Zaimovic A; Moi G; Bussandri M; Raggi MA; Molina E
Int Clin Psychopharmacol; 2003 Sep; 18(5):261-9. PubMed ID: 12920386
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo.
Tauscher-Wisniewski S; Nilsson M; Caldwell C; Plewes J; Allen AJ
J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):713-8. PubMed ID: 17979590
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
Grinenko AIa; Krupitskiĭ EM; Zvartau EE
Vestn Ross Akad Med Nauk; 2003; (10):54-6. PubMed ID: 14598513
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy.
Messinis L; Lyros E; Andrian V; Katsakiori P; Panagis G; Georgiou V; Papathanasopoulos P
Hum Psychopharmacol; 2009 Oct; 24(7):524-31. PubMed ID: 19650155
[TBL] [Abstract][Full Text] [Related]
15. Overcoming opioid blockade from depot naltrexone (Prodetoxon).
Kruptisky EM; Burakov AM; Tsoy MV; Egorova VY; Slavina TY; Grinenko AY; Zvartau EE; Woody GE
Addiction; 2007 Jul; 102(7):1164-5. PubMed ID: 17498182
[TBL] [Abstract][Full Text] [Related]
16. Increased oxytocin levels among abstinent heroin addicts: Association with aggressiveness, psychiatric symptoms and perceived childhood neglect.
Gerra LM; Gerra G; Mercolini L; Manfredini M; Somaini L; Pieri CM; Antonioni M; Protti M; Ossola P; Marchesi C
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():70-76. PubMed ID: 28093220
[TBL] [Abstract][Full Text] [Related]
17. Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessments of aggression in personality-disordered men.
Coccaro EF; Berman ME; Kavoussi RJ; Hauger RL
Biol Psychiatry; 1996 Aug; 40(3):157-64. PubMed ID: 8830948
[TBL] [Abstract][Full Text] [Related]
18. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
19. The prediction of drug dependence from expectancy for hostility while intoxicated.
Walter D; Nagoshi C; Muntaner C; Haertzen CA
Int J Addict; 1990 Oct; 25(10):1151-68. PubMed ID: 2090620
[TBL] [Abstract][Full Text] [Related]
20. Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.
Wang AL; Elman I; Lowen SB; Blady SJ; Lynch KG; Hyatt JM; O'Brien CP; Langleben DD
Transl Psychiatry; 2015 Mar; 5(3):e531. PubMed ID: 25781230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
